Gabriele Picco

We had the 3rd meeting of the UK EOCRC Research Consortium in beautiful Edinburgh yesterday supported by British Society of Gastroenterology (BSG) and @bowelcanceruk.bsky.social attended by over 50 UK academics - celebrating our first project funding success only 1 year after foundation

Very cool story and especially useful mathematical models for everyone to use! Check it out!!!

Epigenetically driven and early immune evasion in colorectal cancer evolution - Nature Genetics This study nominates immune escape as an early event in colorectal cancer and shows how this can be driven through both genetic and epigenetic changes.

New @natgenet.nature.com paper from the brilliant @eszterlakatos.bsky.social presents evidence that chromatin alterations disrupt antigen presentation & neoantigens in colorectal cancer. Also that immune escape is part of the "Big Bang", at the outset of CRC growth. www.nature.com/articles/s41...

Thanks, Isabelle! I was watching you draw while taking notes on the other speaker — very impressed!

Thanks Isabelle. Wonderful experience presenting our work @mgarnett.bsky.social #genomicsatscale25! Thanks for having me!

Somatic mutation and selection at population scale - Nature A new version of nanorate DNA sequencing, with an error rate lower than five errors per billion base pairs and compatible with whole-exome and targeted capture, enables epidemiological-scale studies of somatic mutation and selection and the generation of high-resolution selection maps across coding and non-coding sites for many genes.

Our latest work is out in Nature today. In this paper, we introduce an improved version of NanoSeq, a duplex sequencing protocol with <5 errors per billion bp in single DNA molecules, and use it to study the somatic mutation landscape of oral epithelium in >1000 people www.nature.com/articles/s41...

DNA mutagenesis driven by transcription factor competition with mismatch repair Competition between transcription factors and mismatch repair machinery drives localized hypermutation at regulatory elements, with implications for cancer and genome evolution.

I'm very pleased to announce the official publication of our lab's paper "DNA mutagenesis driven by transcription factor competition with mismatch repair" in today's issue of Cell! www.cell.com/cell/abstrac...

depmap miner logo

The Garnett Lab is excited to launch DepMap Miner, a new tool to explore cancer dependency data!
Built on the Sanger DepMap, the DepMap Miner brings together multi-omic and functional datasets for over 1300 cancer cell models.

Start mining data now: dataminer.depmap.sanger.ac.uk

Fluctuating DNA methylation tracks cancer evolution at clinical scale - Nature Cancer evolutionary dynamics are quantitatively inferred using a method, EVOFLUx, applied to fluctuating DNA methylation.

new out in Nature www.nature.com/articles/s41...

Ongoing genome doubling shapes evolvability and immunity in ovarian cancer - Nature A single-cell sequencing study using more than 30,000 tumour genomes from human ovarian cancers shows that whole-genome doubling is an ongoing mutational process that drives tumour evolution and disru...

Goldschmidt's hopeful monsters in cancer: single cell DNAseq shows whole genome doubling (WGD) is an ongoing and frequent mutational process in ovarian cancer. www.nature.com/articles/s41... beautiful work from @sohrabshah.bsky.social and team

Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers - Nature Genetics The paralogs cytidine diphosphate diacylglycerol synthase 1 and 2 form a potentially targetable synthetic lethal relationship in mesenchymal-like cancers that involves disruption of lipid metabolism.

www.nature.com/articles/s41...

Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers

On behalf of InSiGHT, we are delighted to welcome you to the #InSiGHT2026 meeting in Singapore, taking place from 4 – 7 March 2026 #LynchSyndrome #Polyposis @cgaigc.com @stmarksgenomics.bsky.social

insight2026.org

Changes to the 2026 and 2027 Work Programmes With the launch of the competitions for grants under ERC Work Programme 2026 in July of this year, several changes to the submission of applications and the evaluation of proposals will apply. The mai...

Planning to apply for #research #funding from the ERC?

From the next application rounds, expect changes to the:

• proposal structure
• evaluation process
• extra funding you can request
• eligibility for Starting & Consolidator #Grants (from 2027)

More 👇 europa.eu/!RPHWvv

🚨 Excited to share our latest preprint!
@mgarnett.bsky.social @mattcoelho.bsky.social
We introduce BEstimate, a flexible, comprehensive tool for designing and interpreting CRISPR-based editing experiments.
#CRISPR #BEstimate #BaseEditor

How does tumour heterogeneity arise? How can we predict cancer cell plasticity? In 2 new studies, we trace #glioblastoma heterogeneity to a spatial cancer cell trajectory w. multimodal cell atlassing bit.ly/4mkrWgs & predict plasticity w. snRNA/ATAC+deep learning bit.ly/3FbI6Ic 🧵

Great to see WRN featured in the #AACR25 Special Session on 'Bringing Science to the Clinic: Overcoming Hurdles for Therapeutic Translation.' Grateful to Tim Yap for highlighting our past and ongoing work!

Great talk by Yanhua Rao at #AACR2025 on GSK’s new clinical WRN inhibitor. Proud to see our unpublished data spotlighted for revealing new MoA insights. Exciting times ahead! @mgarnett.bsky.social

CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance Cancer immunotherapy is only effective in a subset of patients, highlighting the need for effective biomarkers and combination therapies. Here we systematically identify genetic determinants of cancer...

A fantastic collaboration with Emile Voest’s lab at NKI, the new @mattcoelho.bsky.social group. WG CRISPR screens in MSI organoids co-cultured with autologous reactive T cells! Amazing work from Alex Watterson! New preprint here: www.biorxiv.org/content/10.1...
#Organoids #Immunotherapy #CRISPR #MSI

6 years from WRN:MSI discovery to first-in-human trial data — incredible. A fantastic journey. Now, hoping for exciting news at AACR and real impact for patients real soon! #CancerResearch

Just landed in Chicago for #AACR25 — Millennium Park in bloom! Excited for team talks on WRN inhibitors in MSI cancers, with first-in-human data discussed by @mgarnett.bsky.social at the Clinical Trials Plenary. I’ll present new data on WRNi-driven evolution — Poster #420! #MSI #SyntheticLethality

Promising early safety and immunogenicity data from the Nous-209 Lynch Syndrome vaccine presented at AACR this month aacrjournals.org/cancerres/ar...

CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance Cancer immunotherapy is only effective in a subset of patients, highlighting the need for effective biomarkers and combination therapies. Here we systematically identify genetic determinants of cancer...

Excited to announce our preprint today @biorxivpreprint.bsky.social
Using functional genomics, we map the genetic determinants cancer cell sensitivity to tumour-reactive T cells:
www.biorxiv.org/content/10.1...

Maurizio si prende il tempo. Ha scritto un libro che spiega il cancro e la ricerca con semplicità, rigore e responsabilità. Da leggere e regalare. Presenterà presto il libro in Italia. Non perdetevelo!

Ho conosciuto @scaltritilab.bsky.social grazie ai suoi lavori, poi l'ho incontrato più volte. Circondato da colleghi e collaboratori, si è sempre fermato a parlare con me, condividendo idee e riflessioni sulla nostra ricerca.

Non è facile parlare di cancro. Trovare le parole giuste senza banalizzare né spaventare, senza annoiare né essere troppo tecnici, non è facile. Parlarne con chiarezza è essenziale.

Quando torno in Italia, mi chiedono spesso: "Di cosa ti occupi adesso?" o "A che punto siamo con la cura del cancro?" Domande semplici, risposte complesse – spesso taglio corto.

Senior scientist – functional genomics Senior scientist – functional genomics Location: Cambridge Salary: Competitive About AstraZeneca AstraZeneca is a global, science-led, and patient-focused biopharmaceutical company that focuses on the...

Please forward to any interested scientists - we're looking for a scientist to work in our functional genomics centre to find new cancer targets in Cambridge, UK. A mix of wet lab as well as computational skills a plus.
astrazeneca.wd3.myworkdayjobs.com/Careers/job/...

Now online in Cancer Discovery: Single-Cell eQTL Mapping Reveals Cell Subtype-Specific Genetic Control and Mechanism in Malignant Transformation of Colorectal Cancer - by Can Chen, Yimin Cai, Wenlong Hu, Kai Tan, Zequn Lu, Xuanyu Zhu, Jianbo Tian, Xiaoping Miao & colleagues doi.org/10.1158/2159...

Work led by Syed Haider and our team at the @breastcancernow.bsky Toby Robins Research Centre @icr.ac.uk and funded by @cancerresearchuk.org

Breaking barriers: we need a multidisciplinary approach to tackle cancer drug resistance - BJC Reports BJC Reports - Breaking barriers: we need a multidisciplinary approach to tackle cancer drug resistance

Today in BJC Reports, we summarise the outcomes from a multidisciplinary workshop focused on addressing cancer drug resistance.
www.nature.com/articles/s44...